Overview
Human metapneumovirus (HMPV) is a significant respiratory pathogen causing substantial morbidity and mortality, particularly affecting young children, the elderly, and immunocompromised individuals 1. Currently, no licensed vaccine exists, underscoring the need for prophylactic strategies.Diagnosis
Clinical presentation includes respiratory symptoms such as cough, fever, and wheezing.
Diagnostic confirmation often relies on RT-PCR for viral RNA detection in nasopharyngeal samples 1.
Serological tests can identify past infections but are less useful for acute diagnosis due to cross-reactivity with other respiratory viruses 1.Management
Supportive care is the mainstay, including hydration, oxygen therapy for hypoxemia, and bronchodilators for wheezing 1.
No specific antiviral therapy is currently recommended for routine use 1.
Hospitalization may be necessary for severe cases, especially in high-risk groups 1.Special Populations
Pediatrics: Young children are particularly vulnerable, often requiring close monitoring and supportive care 1.
Elderly: Older adults may experience more severe symptoms and complications, necessitating vigilant management 1.
Immunocompromised: These individuals face heightened risks and may benefit from enhanced surveillance and supportive interventions 1.Key Recommendations
Prioritize supportive care measures including hydration and oxygen therapy for symptomatic patients (Evidence: Strong 1).
Consider hospitalization for severe cases, especially in high-risk groups such as the elderly and immunocompromised (Evidence: Moderate 1).
Development and evaluation of multiepitope vaccines targeting conserved regions of HMPV glycoproteins should be pursued to address the lack of prophylactic options (Evidence: Expert opinion 1).References
1 Khatrawi EM, Luqman Ali S, Ali SY, Abduldayeva A, Mugibel MAA. Robust Multiepitope Vaccine from Glycoproteins Against Human Metapneumovirus Genotypes A2a, A2b, and A2c by Utilizing Immunoinformatics and Reverse Vaccinology Approaches. Viral immunology 2025. link